Journal of Neural Transmission

, Volume 113, Issue 11, pp 1791–1801

Changes in the activity and protein levels of CSF acetylcholinesterases in relation to cognitive function of patients with mild Alzheimer’s disease following chronic donepezil treatment

  • T. Darreh-Shori
  • L. Meurling
  • T. Pettersson
  • K. Hugosson
  • E. Hellström-Lindahl
  • N. Andreasen
  • L. Minthon
  • A. Nordberg
Article

DOI: 10.1007/s00702-006-0526-2

Cite this article as:
Darreh-Shori, T., Meurling, L., Pettersson, T. et al. J Neural Transm (2006) 113: 1791. doi:10.1007/s00702-006-0526-2

Summary.

Objectives. To evaluate long-term changes in acetylcholinesterase (AChE) activity in CSF and blood following donepezil treatment in relation to the concentration of donepezil and cognition in AD patients.

Methods. CSF or blood (or both) samples of a total of 104 patients with mild AD were used [MMSE score 23 ± 0.4; age 75 ± 1 years (mean ± SEM); n = 53 for CSF and n = 51 for plasma/red blood cell (RBC) samples]. The patients were treated with 5 or 10 mg/day donepezil and clinically followed for 2 years. The CSF and RBC AChE activities were measured by the Ellman’s direct colorimetric assay. Protein levels of two variants of AChE (“read-through” AChE-R and synaptic AChE-S) were determined by an ELISA-like method.

Results. The plasma donepezil concentration was dose-dependent (between 30 and 60 ng/mL in the 5-mg and 10-mg group, respectively). The CSF donepezil concentration was 10 times lower than the plasma level and showed dose- and time-dependent kinetics. The RBC AChE inhibition was moderate (19–29%). CSF AChE-S inhibition was estimated to 30–40% in the 5-mg and 45–55% in the 10-mg group. Positive correlations were observed between the CSF AChE inhibition, an increased protein level of the AChE-R variant and MMSE examination. Patients with high AChE inhibition (≥45%) showed a stabilized MMSE test result after up to two years, while a significant decline was observed in AD patients with lower AChE inhibition (≤30%).

Conclusions. An increase in the protein level of the AChE-R variant corresponded to a high AChE inhibition in CSF and favored less cognitive deterioration.

Keywords: Alzheimer’s disease, acetylcholinesterase, acetylcholinesterase splice variants, cholinesterase inhibitors, cerebrospinal fluid (CSF), red blood cells (RBC), chronic treatment, donepezil 

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • T. Darreh-Shori
    • 1
  • L. Meurling
    • 3
  • T. Pettersson
    • 3
  • K. Hugosson
    • 1
  • E. Hellström-Lindahl
    • 1
  • N. Andreasen
    • 2
  • L. Minthon
    • 4
  • A. Nordberg
    • 1
    • 2
  1. 1.Division of Molecular Neuropharmacology, Department of Neurobiology, Care Sciences and Society, Karolinska InstituteKarolinska University Hospital HuddingeStockholmSweden
  2. 2.Department of Geriatric MedicineKarolinska University Hospital HuddingeStockholmSweden
  3. 3.Labmedicin, Division for Clinical PharmacologyKarolinska University Hospital HuddingeStockholmSweden
  4. 4.Neuropsychiatric ClinicUniversity Hospital MASMalmöSweden

Personalised recommendations